These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32014459)

  • 1. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
    Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
    Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
    Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
    Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
    Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
    Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
    Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
    Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
    Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
    Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma.
    Chong PSY; Chooi JY; Lim SLJ; Chung TH; Brunmeir R; Leow ACY; Toh SHM; Balan K; Azaman MIB; Wu Z; Subramaniam N; Vardy LA; Chng WJ
    Haematologica; 2024 Jun; 109(6):1893-1908. PubMed ID: 38124661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
    Ezponda T; Popovic R; Shah MY; Martinez-Garcia E; Zheng Y; Min DJ; Will C; Neri A; Kelleher NL; Yu J; Licht JD
    Oncogene; 2013 Jun; 32(23):2882-90. PubMed ID: 22797064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
    Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
    Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
    Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
    Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome.
    Sobh A; Encinas E; Patel A; Surapaneni G; Bonilla E; Kaestner C; Poullard J; Clerio M; Vasan K; Freeman T; Lv D; Dupéré-Richer D; Riva A; Barwick BG; Zhou D; Boise LH; Mitsiades CS; Kim B; Bennett RL; Chandel NS; Licht JD
    Blood; 2024 Jul; 144(3):283-295. PubMed ID: 38598835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
    Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
    Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
    Keats JJ; Maxwell CA; Taylor BJ; Hendzel MJ; Chesi M; Bergsagel PL; Larratt LM; Mant MJ; Reiman T; Belch AR; Pilarski LM
    Blood; 2005 May; 105(10):4060-9. PubMed ID: 15677557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma.
    Xie Z; Gunaratne J; Cheong LL; Liu SC; Koh TL; Huang G; Blackstock WP; Chng WJ
    Oncotarget; 2013 Jul; 4(7):1008-18. PubMed ID: 23900284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
    Chen S; Chen JZ; Zhang JQ; Chen HX; Yan ML; Huang L; Tian YF; Chen YL; Wang YD
    Cancer Lett; 2016 Dec; 383(1):73-84. PubMed ID: 27693633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities.
    Yang F; Sun L; Li Q; Han X; Lei L; Zhang H; Shang Y
    EMBO J; 2012 Jan; 31(1):110-23. PubMed ID: 21983900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1.
    Cao J; Wang X; Dai T; Wu Y; Zhang M; Cao R; Zhang R; Wang G; Jiang R; Zhou BP; Shi J; Kang T
    Theranostics; 2018; 8(10):2739-2751. PubMed ID: 29774072
    [No Abstract]   [Full Text] [Related]  

  • 17. Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.
    Han X; Piao L; Yuan X; Wang L; Liu Z; He X
    Int J Med Sci; 2019; 16(10):1404-1411. PubMed ID: 31692936
    [No Abstract]   [Full Text] [Related]  

  • 18. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-2392 suppresses metastasis and epithelial-mesenchymal transition by targeting
    Li J; Li T; Lu Y; Shen G; Guo H; Wu J; Lei C; Du F; Zhou F; Zhao X; Nie Y; Fan D
    FASEB J; 2017 Sep; 31(9):3774-3786. PubMed ID: 28512191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
    Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
    Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.